TSCAN THERAPEUTICS, INC. (TCRX) Spending and interest coverage
- R&D / revenue · 12 months: Value 1364.56%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 138.39%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -43.22×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 1364.56% | Research and development expense / revenue. Period ending 2026-06-30. $97.03M ÷ $7.11M × 100 ≈ 1364.56% |
| Stock-based compensation / revenue · 12 months | 138.39% | Share-based compensation / revenue. Period ending 2026-06-30. $9.84M ÷ $7.11M × 100 ≈ 138.39% |
| Interest coverage · 12 months | -43.22× | Operating income ÷ reported interest expense. $-120.54M ÷ $2.79M ≈ -43.22× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 97.03M USD | Research and Development Expense |
| Revenue | 7.11M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 9.84M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -120.54M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 2.79M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $97.03M | $7.11M | $9.84M | $-120.54M | $2.79M | 1364.56% | 138.39% | -43.22× | Reported |
| 2026-03-31 | $106.27M | $9.14M | $10.76M | $-128.70M | $2.78M | 1163.16% | 117.74% | -46.31× | Reported |
| 2025-12-31 | $114.15M | $10.32M | $11.71M | $-135.81M | $2.77M | 1105.57% | 113.38% | -49.05× | Reported |
| 2025-09-30 | $123.47M | $8.42M | $12.41M | $-148.67M | $2.85M | 1465.81% | 147.36% | -52.15× | Reported |
| 2025-06-30 | $118.04M | $6.96M | $11.92M | $-144.24M | $3.11M | 1695.70% | 171.30% | -46.38× | Reported |
| 2025-03-31 | $112.28M | $4.42M | $10.98M | $-139.70M | $3.37M | 2539.72% | 248.34% | -41.42× | Reported |
| 2024-12-31 | $107.35M | $2.82M | $9.55M | $-134.82M | $3.65M | 3812.14% | 339.10% | -36.91× | Reported |
| 2024-09-30 | $100.40M | $9.36M | $8.34M | $-119.47M | $3.72M | 1072.44% | 89.03% | -32.11× | Reported |
| 2024-06-30 | $96.88M | $12.20M | $7.15M | $-111.59M | $3.75M | 794.11% | 58.63% | -29.80× | Reported |
| 2024-03-31 | $91.23M | $14.81M | $6.04M | $-102.09M | $3.76M | 615.93% | 40.81% | -27.14× | Reported |
| 2023-12-31 | $88.15M | $21.05M | $5.21M | $-93.46M | $3.76M | 418.80% | 24.74% | -24.86× | Reported |
| 2023-09-30 | $81.35M | $16.93M | $5.00M | $-90.75M | $3.88M | 480.43% | 29.56% | -23.38× | Reported |
| 2023-06-30 | $73.64M | $16.41M | $4.91M | $-82.58M | $3.10M | 448.78% | 29.92% | -26.63× | Reported |
| 2023-03-31 | $66.91M | $17.32M | $4.71M | $-73.22M | (m) | 386.37% | 27.22% | (m) | (m) |
| 2022-12-31 | $59.82M | $13.54M | $4.55M | $-66.64M | $1.18M | 441.96% | 33.62% | -56.66× | Reported |
| 2022-09-30 | $56.82M | $13.29M | $4.04M | $-62.19M | (m) | 427.43% | 30.37% | (m) | (m) |
| 2022-06-30 | $56.00M | $12.34M | $3.68M | $-61.45M | (m) | 453.68% | 29.79% | (m) | (m) |
| 2022-03-31 | $52.30M | $11.13M | $3.16M | $-56.89M | (m) | 469.74% | 28.34% | (m) | (m) |
| 2021-12-31 | $44.95M | $10.14M | $2.52M | $-48.64M | (m) | 443.29% | 24.81% | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $20.58M | $1.08M | $515.00K | $-26.23M | (m) | 1896.50% | 47.47% | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |